xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
amitriptylin abcur filmuhúðuð tafla 50 mg
abcur ab* - amitriptylinum hýdróklóríð - filmuhúðuð tafla - 50 mg
amitriptylin abcur filmuhúðuð tafla 10 mg
abcur ab* - amitriptylinum hýdróklóríð - filmuhúðuð tafla - 10 mg
amitriptylin abcur filmuhúðuð tafla 25 mg
abcur ab* - amitriptylinum hýdróklóríð - filmuhúðuð tafla - 25 mg
noritren tafla 10 mg
h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 10 mg
noritren tafla 25 mg
h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 25 mg
noritren tafla 50 mg
h. lundbeck a/s* - nortriptylinum hýdróklóríð - tafla - 50 mg
quetiapin krka forðatafla 150 mg
krka sverige ab - quetiapinum fúmarat - forðatafla - 150 mg
quetiapin krka forðatafla 200 mg
krka sverige ab - quetiapinum fúmarat - forðatafla - 200 mg
quetiapin krka forðatafla 300 mg
krka sverige ab - quetiapinum fúmarat - forðatafla - 300 mg